Fischer’s appointment goes into effect on Oct. 1, 2023. He succeeds Helen Giza, who took over as CEO and board chair in December 2022. She took on the corner office after CEO Carla Kriwet decided to leave the company “at her own request and by mutual agreement due to strategic differences.” Giza continued to serve as acting CFO over the past seven months.
“Martin Fischer has proven that he can successfully drive fundamental change in organizations,” Giza said in a news release. “In our organizational transformation and turnaround management, we will benefit from his finance and healthcare expertise. Martin will be an important contributor to the execution of our strategy in unlocking value as the leading kidney care company.”
Based in Bad Homburg, Germany, Fischer takes on responsibilities for the global finance organization of Fresenius. Once the company’s proposed change of form from KGaA to German stock corporation goes through, Fischer will also become a member of the board.
Fischer previously served as head of finance for Siemens Healthineers’ diagnostics division, taking on that position in 2019. Before that, he headed the board office and organizations function for Siemens Healthineers. He led the business plan and operating model development for the company’s IPO in March 2018.
Additionally, Fischer held a number of key international operational and finance positions within Siemens AG.
“There are great challenges ahead of us,” Fischer said. “I am convinced of the company’s potential and look forward to realizing it together with the global team of Fresenius Medical Care. I am excited to bring my experience and expertise to support the company’s transformation.”
